Oaktree Specialty Lending (NASDAQ:OCSL – Get Free Report) issued its quarterly earnings data on Tuesday. The credit services provider reported $0.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.34, Zacks reports. Oaktree Specialty Lending had a net margin of 14.23% and a return on equity of 9.40%. The company had revenue of $68.01 million during the quarter, compared to the consensus estimate of $69.97 million.
Here are the key takeaways from Oaktree Specialty Lending’s conference call:
- Credit performance improved: Non-accruals fell to 1.8% of debt investments at fair value from 3.0% a year earlier, with six companies on non-accrual versus 10. BioXcel’s sale and subsequent FDA approval are expected to deliver lenders a milestone payment above the company’s carrying mark, while RumbleOn repaid OCSL’s loan at 101.
- Earnings declined: Fourth-quarter adjusted net investment income fell to $29.6 million, or $0.34 per share, from $32.2 million, or $0.37, in the prior quarter. Full-year adjusted net investment income also decreased to $1.49 per share from $1.76.
- Balance sheet flexibility remained solid: Net leverage ended the year at 1.00x, within the company’s 0.9x–1.25x target range, and pro forma liquidity was about $689 million. OCSL issued $300 million of five-year notes, leaving its next debt maturity in February 2029 after the January 2027 notes are repaid.
- Higher rates offer income upside but could pressure borrowers: With 91% of debt investments floating rate, management estimates each 25-basis-point rate increase adds slightly more than half a cent per share per quarter to adjusted net investment income once fully reset. Borrower interest coverage is 2.3x currently and is estimated at 2.1x after a 100-basis-point increase.
- Investment activity showed signs of strengthening: OCSL committed $179 million to new investments in the quarter at a 9.6% weighted average yield, with spreads wider than the cited market range. Management said its pipeline had built since late September and it originated about $80 million of commitments in October.
Oaktree Specialty Lending Price Performance
NASDAQ OCSL opened at $11.90 on Thursday. The company has a quick ratio of 0.19, a current ratio of 0.19 and a debt-to-equity ratio of 0.68. Oaktree Specialty Lending has a 12-month low of $10.63 and a 12-month high of $13.90. The company has a market capitalization of $1.05 billion, a PE ratio of 25.87 and a beta of 0.50. The firm’s 50 day moving average is $12.03 and its 200-day moving average is $12.05.
Oaktree Specialty Lending Cuts Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Tuesday, December 15th will be issued a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.7%. This is a drop from Oaktree Specialty Lending’s previous quarterly dividend of $0.03. The ex-dividend date is Tuesday, December 15th. Oaktree Specialty Lending’s dividend payout ratio is 260.87%.
Analyst Ratings Changes
Several equities research analysts recently commented on the stock. Weiss Ratings cut shares of Oaktree Specialty Lending from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Keefe, Bruyette & Woods lowered their target price on Oaktree Specialty Lending from $13.50 to $12.50 and set a “market perform” rating for the company in a report on Wednesday. Citigroup started coverage on Oaktree Specialty Lending in a research note on Monday, October 26th. They issued a “market perform” rating on the stock. Citizens Jmp assumed coverage on Oaktree Specialty Lending in a research note on Monday, October 26th. They issued a “market perform” rating on the stock. Finally, B. Riley Financial restated a “neutral” rating on shares of Oaktree Specialty Lending in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $12.00.
Check Out Our Latest Stock Analysis on OCSL
Oaktree Specialty Lending Company Profile
Oaktree Specialty Lending Corporation is a business development company that provides financing to middle-market companies. It is externally managed by Oaktree Fund Advisors, an affiliate of Oaktree Capital Management. The company invests primarily in privately negotiated debt, including first- and second-lien loans, subordinated debt and mezzanine financing. It may also make preferred equity and other equity investments, often alongside its debt investments. Oaktree Specialty Lending focuses mainly on companies in the United States, seeking to provide flexible financing for business growth, acquisitions, recapitalizations and other corporate needs.
Featured Stories
- Five stocks we like better than Oaktree Specialty Lending
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Oaktree Specialty Lending Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oaktree Specialty Lending and related companies with MarketBeat.com's FREE daily email newsletter.
